Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

747
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
747
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.4K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.4K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population.

European heart journal·2026
Same author

Realizing the full potential of registry-based randomized controlled trials.

Journal of clinical epidemiology·2026
Same author

Authors' reply: Poor long-term cardiovascular risk factor management after acute coronary syndrome: An observational cohort study.

Journal of internal medicine·2026
Same author

Mental disorders, psychotropic drug dispensation and unfavourable sociodemographic factors in patients with myocardial infarction with and without obstructive coronary arteries.

International journal of cardiology. Cardiovascular risk and prevention·2026
Same author

Improvements in the spatial resolution of coronary magnetic resonance angiography enhance the diagnostic performance in comparison to quantitative coronary angiography.

European heart journal. Imaging methods and practice·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients. Reply.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K

Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.

Anna Meta Dyrvig Kristensen1, Xavier Rossello2,3,4,5, Dan Atar6,7

  • 1Department of Cardiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen.

The New England Journal of Medicine
|November 10, 2025
PubMed
Summary
This summary is machine-generated.

Beta-blocker therapy did not significantly reduce the risk of death, myocardial infarction, or heart failure in patients with preserved left ventricular ejection fraction (LVEF) after myocardial infarction. This finding challenges the routine use of beta-blockers in this specific patient group.

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.6K
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

28.6K

Related Experiment Videos

Last Updated: Jan 11, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K
Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.6K
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

28.6K

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • The efficacy of beta-blockers in post-myocardial infarction patients with preserved left ventricular ejection fraction (LVEF) remains uncertain.
  • Current guidelines do not consistently recommend beta-blocker therapy for all patients post-myocardial infarction, particularly those with normal LVEF.

Purpose of the Study:

  • To evaluate the effectiveness of beta-blocker therapy in patients with myocardial infarction and a left ventricular ejection fraction (LVEF) of at least 50%.
  • To determine if beta-blockers reduce the composite endpoint of death, myocardial infarction, or heart failure in this specific population.

Main Methods:

  • Individual-patient data meta-analysis of five randomized controlled trials.
  • Inclusion criteria: recent myocardial infarction, LVEF ≥ 50%, no other beta-blocker indications.
  • Primary endpoint: composite of all-cause death, myocardial infarction, or heart failure, analyzed using Cox proportional-hazards model.

Main Results:

  • 17,801 patients were analyzed (8831 received beta-blockers, 8970 did not) with a median follow-up of 3.6 years.
  • No significant difference in the primary composite endpoint between the beta-blocker and no-beta-blocker groups (HR, 0.97; 95% CI, 0.87-1.07).
  • Subgroup analyses for all-cause death, myocardial infarction, and heart failure also showed no significant benefit.

Conclusions:

  • Beta-blocker therapy did not demonstrate a reduction in the composite endpoint of death, myocardial infarction, or heart failure in patients with myocardial infarction and preserved LVEF.
  • These findings suggest that routine beta-blocker use may not be beneficial for patients with myocardial infarction and an LVEF of 50% or higher without other compelling indications.